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Key Points 
Question 
Does low-dose cyclophosphamide (CPM) ±MVA-5T4 (TroVax) enhance anti-tumor 
immunity in metastatic colorectal cancer (mCRC) patients in a randomized controlled trial?  
Findings 
All three treatment regimens of CPM-only, TroVax-only and combination demonstrated 
encouraging anti-tumor immunological responses, prolonging survival with no safety 
concerns. The addition of CPM made no difference to the number of patients responding 
to TroVax; however, this is the first randomized trial demonstrating improved survival 
outcomes of mCRC patients with low-dose CPM.  
Meaning 
These data support the importance of well-targeted anti-tumor immune responses, show 
the safety and anti-tumor activity of both low-dose CPM and TroVax, and support further 
investigation in mCRC.  
	 3 
Abstract 
Importance The success of immunotherapy with checkpoint inhibitors is not replicated in 
most cases of colorectal cancer, so different strategies are urgently required. The 
oncofetal antigen 5T4 is expressed in >90% of metastatic colorectal cancer (mCRC). 
Preliminary data using a 5T4-expressing vaccine (TroVax) in mCRC demonstrated it safely 
induced serological and T-cell responses.  
Objective TroVax was combined with metronomic low dose cyclophosphamide (CPM), as 
a regulatory T-cell (Treg)-depleting agent to determine whether anti-tumor immunity could 
be boosted, in an open randomized study in mCRC.  
Design, Setting and Participants Between July 9, 2012, and February 8, 2016, fifty-five 
inoperable mCRC patients with prior stable disease following standard chemotherapy, 
were enrolled at a single-center and randomized to groups 1: no treatment (n=9); 2: CPM 
(n=9); 3: TroVax (n=19); 4: combination of TroVax and CPM (n=18).  
Interventions Patients randomized to a CPM group received 50mg b.i.d. on treatment 
days 1-7 and 15-21. Patients randomized to a TroVax group received at a dose of 1x109 
TCID50 as an intramuscular injection at treatment days 22, 36, 50, 64, 78 and 106. 
Main Outcomes and Measures The pre-defined primary endpoint was the magnitude of 
anti-5T4 immune responses (5T4-specific T-cells and antibodies) generated at treatment 
week 7. Secondary endpoints included analysis of the kinetics of anti-5T4 responses, 
progression-free survival (PFS) and overall survival (OS). 
Results 5T4-specific immune responses were significantly increased in groups 3 (p=.02) 
and 4 (p=.002). CPM depleted Tregs in 24/27 patients, independently prolonging PFS (5.0 
vs. 2.5 months, HR=0.48, 95%-CI 0.21-1.11, p=.09). TroVax doubled baseline anti-5T4 
responses in 16/35 patients, resulting in significantly prolonged PFS (5.6 vs. 2.4 months, 
HR 0.21, 95%-CI 0.090-0.47, p<.001) and OS (20.0 vs. 10.3 months, HR=0.32, 95%-CI 
0.14-0.74, p=.008). No grade 3/4 adverse events were observed. 
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Conclusion and Relevance This is the first randomized immunotherapy study 
demonstrating a significant survival benefit in mCRC. Prior depletion of Tregs by CPM 
does not boost immune responses generated to TroVax vaccination, however both CPM 
and TroVax independently induced beneficial anti-tumor immune responses resulting in 
prolonged survival without toxicity. Larger clinical trials are planned to further validate 
these data.	
Trial Registration EudraCT: 2010-024380-41. ISRCTN registry: ISRCTN54669986. 
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Introduction  
Colorectal cancer is the second leading cause of death from cancer.1 Although early 
stages are often cured by surgical resection, the prognosis for patients with metastatic 
colorectal cancer (mCRC) is very poor, with a 5-year survival rate of 7%.2  
There is a clear unmet need for improved therapies; whilst immunotherapy has been at the 
forefront of recent advances, results in CRC have been disappointing. Over 96% of mCRC 
patients have microsatellite stable tumors3 that do not respond to current immunotherapies, 
possibly due to decreased incidence of neo-antigens.4-6 We hypothesized that in these 
patients, a well-targeted immune response against an upregulated tumor antigen, with 
minimal expression on healthy background tissues, represents a potentially more powerful 
therapy. One candidate is 5T4, a trophoblast glycoprotein with restricted expression to 
several human adenocarcinomas including >90% of CRCs.7,8 Previously, we 
demonstrated that 5T4-specific IFN-g+ T-cell responses correlate with tumor stage 
providing protection against metastasis.9,10 Here, we sought to improve 5T4 immune 
responses in mCRC patients by vaccinating with an immunogenic, non-replicating 
modified vaccinia Ankara (MVA) vector encoding the 5T4 antigen (TroVax). This vaccine 
has demonstrated efficacy in pre-clinical models of colon cancer via the induction of 
humoral anti-5T4 responses.11 Early indications in mCRC patients demonstrated an 
excellent safety profile, with the induction of anti-5T4 responses correlating with disease 
control, thus warranting further studies in randomized trials.12 
Previous attempts at vaccination strategies targeting upregulated tumor antigens have 
been largely unsuccessful for many tumor types; however a recent trial of MVA-MUC in 
advanced NSCLC demonstrated profound improvement to PFS.13 Such vaccines work by 
inducing the intracellular expression of their respective transgene allowing the tumor 
antigen to be processed by MHC class-I and –II pathways. Given that activation of the 
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adaptive immune response may concurrently stimulate tumor-specific regulatory T-cells 
(Tregs), we also sought to test the hypothesis that the effectiveness of cancer vaccines is 
improved by prior administration of a Treg depleting agent. In low-doses, CPM has 
demonstrated numerous immune potentiating effects, most notably the depletion and 
reduced functionality of Tregs.14,15 However, to date, low-dose metronomic CPM has not 
been evaluated in a randomized-controlled setting for cancer.  
The trial reported herein is a randomized phase 1/2 trial in patients with inoperable, mCRC, 
aiming to assess the effectiveness of CPM to boost the immunotherapeutic potential of 
TroVax. We present the final analyses of primary and secondary endpoints, including an 
assessment of how anti-5T4 immune responses and Treg depletion associates with 
patient survival. 
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Methods 
Study design and participants 
This open-label study was performed in a single-centre in the Clinical Research Facility, 
University Hospital of Wales, UK. Patients were evaluated for recruitment at Velindre NHS 
Trust and the South West Wales Cancer Centre, UK. Patients were eligible if they had 
inoperable stage-IV CRC, providing they had evidence of responding or stable disease 
within 4-weeks of trial entry. Previous findings indicate that patients receiving palliative 
chemotherapy can safely be given protracted breaks, i.e. chemotherapy "holidays", with no 
evidence of a worsening of their outcome.16 However, patients with elevated platelet 
counts (>400,000/µl) did not tolerate chemotherapy-free intervals and were excluded from 
this study. Additional exclusion criteria included haemoglobin <11g/dL, monocyte count 
>80,000/µl, completion of first-line chemotherapy <2 weeks from start of treatment, 
clinically apparent autoimmune disease, or those receiving immunosuppressants. Key 
inclusion criteria included WHO performance status 0-2, lymphocyte count ≥500/µl and 
neutrophil count >1200/µl. 
All patients gave written, informed consent personally prior to trial inclusion. The Gene 
Therapy Advisory Committee (GTAC175) and the Cardiff and Vale Ethics committee 
approved the study. Trial authorization was granted from the Medicines and Healthcare 
products Regulatory Authority. This trial is registered with EudraCT (2010-024380-41), the 
ISRCTN registry (ISRCTN54669986) and was conducted in compliance to ICH-GCP 
regulatory requirements. 
Randomization and masking 
The trial was based on a 2x2 factorial design. Patients were randomized 1:1 between 
receiving CPM and not, and 2:1 between receiving TroVax and not, giving rise to four 
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treatment arms: Control (unless clinically indicated; group 1), metronomic CPM only (group 
2), TroVax only (group 3), or CPM & TroVax (group 4). Randomization was undertaken at 
the Clinical Trials Office, University Hospital of Wales, using an un-stratified balanced 
block design, with the outcome communicated to the attending physician immediately 
upon randomization, but after participant enrollment. Treatment allocation was not masked 
in this open-label study. 
Procedures 
50mg CPM (Pharmacia Ltd.) was orally administered twice-a-day on treatment days-
(TD)1-7 and 15-21 or until patient relapsed. Groups 2&4 patients were contacted by phone 
during CPM treatment to ensure compliance. 1x109 TCID50 TroVax (Oxford BioMedica) 
was administered as an intramuscular injection at TD22, 36, 50, 64, 78 and 106. 
Peripheral blood samples were taken at regular intervals (see schematic; figure 1).  
We performed physical examinations and full blood count, urea and electrolytes, and liver 
function tests at each blood test visit. Tumor burden was assessed quantitatively using 
RECIST criteria following CT scans of the abdomen and chest at treatment week 12. 
Beyond 16-weeks of treatment, assessments were performed every 12-weeks until 
documented disease progression, whereby the patient would be treated with standard 
chemotherapy as indicated. 
To assess immunological responses, peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized blood samples by centrifugation over Ficoll, and cultured in 
triplicate with 5T4 peptide pools or control antigens for 14-days. IFN-g ELISpot assays 
were performed to assess for 5T4-specific T-cell responses, as previously described.10 
Positive responses were identified as having at least 20 spot-forming cells (SFC) per 105 
cultured PBMC, and double the number of spots above background.  
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To perform T-cell counts, 3µl CD3-APC, CD4-PE and CD8-PerCPCy5.5 were added to 
50µl of whole heparinized blood using a reverse pipetting technique. Red blood cells were 
lysed before addition of 50µl CountBright Beads (ThermoFisher); samples were acquired 
on a FACSCanto II (BD) and cell counts calculated according to manufacturer instructions. 
To calculate the proportion of CD4+ T-cells expressing Foxp3, fresh PBMC were stained 
with Live/Dead-Aqua, stained with CD4-APCh7, followed by fixation/permeabilization and 
intracellular staining with Foxp3-APC.  
Plasma samples were collected from blood separated over Ficoll to measure 5T4-specific 
antibodies, determined using semi-quantitative ELISA, as previously described.17 
Polyclonal plasma positive for 5T4 was used as a standard curve for each assay. A 2-fold 
increase in 5T4 antibody relative units (RU) was established as the level at which a <1% 
false-positive rate could be expected, and antibody levels were considered positive above 
this value. 
Outcomes 
Given the trials’ primary objective to measure the effect of TroVax and/or CPM on anti-
tumor immune responses, the primary endpoint was the magnitude of 5T4-specific 
responses at TD43 (week 7). Secondary endpoints included the kinetics of anti-5T4 
immune responses over time, PFS, OS, treatment-emergent adverse events, and Treg 
depletion during CPM treatment. PFS was defined as the time from date of trial 
randomization to the date of first documented tumor progression, as determined by 
evidence of radiological progression on CT scan, or clinical deterioration as assessed by 
the oncologist. OS was defined as the time from date of trial randomization to date of 
death due to any cause. 
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To assess safety, we reported adverse event occurrences to the Data Monitoring and 
Ethics Committee after every six completed patients in group 4. Safety in this group was 
assessed weekly for the first 4 weeks. 
Statistical analysis 
Follow-up is complete to Dec 13, 2016, whereby all patients had progressed or received 
other treatments. Power was based on the average effect size expected for each 
treatment, allowing for possible synergy between the two treatments. A randomization of 
27 versus 27 patients to receive CPM or not gave 80% power to detect a moderate 
difference of 0.8 standard deviation in anti-tumor immune response, or other laboratory 
markers. For TroVax randomization, a total of 54 patients (allocated as 36 versus 18) gave 
80% power to detect a difference of 0.83 points between TroVax or not. As the possible 
synergy between CPM and TroVax is of interest, the TroVax randomization is in a ratio of 
2:1; if such synergy is seen, then a comparison of adding CPM to TroVax will contain 36 
patients, enough to see a difference of 1 standard deviation with 80% power. 
All analyses were performed on an intention-to-treat basis with patients ineligible for the 
trial excluded. Wilcoxon matched-pairs signed-rank tests were used to compare non-
parametric datasets, including the assessment of Treg depletion during CPM treatment 
and 5T4 immune responses generated; patients were subdivided based on these results, 
according to endpoints stipulated in the trial protocol. OS and PFS were analyzed using 
log-rank tests and displayed using Kaplan–Meier plots. Categorical data analysis was 
performed using stratified Mantel-Haenszel tests. Effect sizes are displayed as Peto odds 
ratios with 95% confidence intervals. Analyses of each treatment were performed stratified 
for the other treatment allocation within the factorial design and stratified results displayed 
as Forest plots. A p-value less than 0.05 was considered statistically significant and all 
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tests of significance were 2-sided. Analyses were performed using SAS v9.4 and 
GraphPad Prism v7. 
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Results 
Between July 2012 and February 2016, 55 patients were recruited and randomized. One 
patient from group 3 withdrew consent before receiving the allocated intervention, and one 
patient from group 1 and another from group 3 were later found to have undergone a 
curative procedure pre-enrolment (figure 2). These three patients were not included in the 
analyses of immune responses and PFS/OS, however an additional patient was recruited 
to group 3 and was included in the analyses, hence 52 patients could be evaluated. The 
baseline characteristics of the patients randomized to the four groups are shown (table 1). 
All patients presented with liver, lung and/or peritoneal metastases.  
The key objective of the study was to determine the effect of low-dose CPM on anti-tumor 
immune responses, and whether such treatment could enhance immune responses 
generated by TroVax vaccination. CPM alone induced many immunological perturbations, 
most evident being a striking increase in IFN-g+ 5T4-specific T-cell responses, and the 
depletion of Foxp3+ Tregs (24/27 group 2&4 patients (figure 3)); significant depletions in 
Tregs were noted during treatment week 3 at both TD15 (p=.01) and TD18 (p=.003), in 
comparison to TD1 (figure 3B). Setting a threshold of a decrease in absolute Treg 
numbers (i.e. %Treg depletion) above the upper 95%-CI interval (figure 3C), these patients 
exhibited prolonged median PFS over non-responding patients (HR=0.48 95%-CI 0.21-
1.11; p=.09; figure 3D, and shown stratified by TroVax, eFigure 1). Hence effective CPM-
induced Foxp3+ Treg depletion was associated with prolonged PFS, but statistical 
significance was probably not reached due to sample size and the study not being 
powered to directly address this. Treg numbers return to baseline by TD29 in CPM-only 
treated patients and remained at this level for the duration of the trial (data not shown). 
The presence of anti-5T4 immune responses was analysed throughout the trial. Significant 
increases in 5T4 antibodies were evident following two vaccinations at TD43 (group 3 vs.1, 
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p=.02, group 4vs.1, p=.002, figure 4A) hence the primary endpoint was met. Following this, 
5T4 antibody levels increased further for many patients, e.g. treatment day 78 (group 
3vs.1, p<.001, group 4vs.1, p=.003, figure 4A). Despite a trend for group 4 patients 
exhibiting larger increases over group 3 in anti-5T4 antibody titres (and corresponding anti-
MVA titres; eFigure 2) at TD64, 78 and 106, this was not significant. Anti-MVA antibodies 
emerged at similar time-points, yet only small non-significant reductions were noted in 5T4 
antibodies after TD64. When analysing secondary endpoints, development of 5T4 
antibodies was consistent amongst TroVax-treated patients, with 15/17 group 3 and 13/18 
group 4 patients mounting a >2-fold increase in anti-5T4 antibodies at some time during 
the trial (figure 4B). There was one instance of a CPM-only treated patient also mounting a 
doubled anti-5T4 antibody response during treatment (figure 4B). 
The maximum increase in baseline 5T4-specific IFN-g+ T-cell responses revealed varying 
degrees of T-cell response to TroVax vaccination, with 20/35 patients mounting a >2-fold 
increase. Amongst groups 1&2, 10/17 patients mounted a >2-fold increase, owing mostly 
to CPM increasing anti-5T4 T-cell responses via Treg depletion (figure 4B). 
When considering all trial participants that generated >2-fold increase in both anti-5T4 T-
cell and antibody responses to CPM or TroVax at any instance during the trial (filled 
triangles/circles; figure 4B), this was associated with prolonged PFS (5.7 vs. 2.4 months, 
HR=0.58, 95%-CI 0.31-1.09, P=.09; eFigure 3A) and OS (20.0 vs. 13.1 months, HR=0.56, 
95%-CI 0.28-1.12, p=.10; eFigure 3B). Amongst groups 3&4 TroVax-treated patients, this 
effect becomes more apparent since removing groups 1&2 patients from the analysis 
reveals a highly significant difference in PFS (5.6 vs. 2.4 months, HR 0.21, 95%-CI 0.090-
0.47, p<.001; figure 4C) and OS (20.0 vs. 10.3 months, HR=0.32, 95%-CI 0.14-0.74, 
p=.008; figure 4D). Large increases in MVA titres to TroVax also significantly associated 
with PFS (HR=0.26, 95%-CI 0.11-0.59, p=.001; eFigure 2B&C) but not OS (p=.36; eFigure 
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2B&D), hence general immunological responsiveness of the patient may also determine 
outcome.  
Although beneficial immunological responses to CPM or TroVax were independently 
associated with prolonged PFS over group 1, neither treatment was more effective than 
the other (eFigure1 and eFigure 4A&B), nor did combination group 4 patients exhibit 
improved survival over TroVax-only group 3 (figures 5A&B). 7/18 group 4 patients 
mounted 5T4 T-cell and antibody responses at any point in the trial, yet this was no better 
than in the 9/17 group 3 patients mounting similar responses to TroVax alone (p=.60; 
eFigure1A). Therefore, the addition of CPM does not enhance the effectiveness of TroVax, 
nor does it appear detrimental to boosting response to vaccination.  
All three treatment groups demonstrated improved PFS but not OS over no treatment 
controls (figures 5C&D); overall survival data is difficult to interpret given that subsequent 
interventions offered to these patients is beyond our control. Group 2 patients 
demonstrated the greatest increase in median PFS over group 1 (HR=0.32, 95%-CI 0.094-
1.09, P=.07; figure 5A), although the number of patients is low. Therefore, in mCRC 
patients, being treated with either TroVax or low-dose CPM was more effective than 
allowing a protracted chemotherapy “holiday”. In addition, there were no instances of 
treatment-related grade 3/4 adverse events (eTable 2), suggesting an excellent safety 
profile of these interventions. 
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Discussion 
This randomized study demonstrated the clinical benefit of both a vaccine and low-dose 
CPM in the treatment of mCRC. Each treatment improved anti-tumor immunity via different 
mechanisms; CPM was effective at depleting Foxp3+ Tregs, resulting in boosted anti-5T4 
T-cell responses, which associated with survival, and TroVax was effective at inducing 
cellular and humoral anti-5T4 responses, again to the benefit of patient PFS and OS in a 
subgroup analysis of responders versus non-responders. In combination however, CPM 
did little to improve anti-5T4 responses during TroVax treatment, despite a modest 
increase in anti-5T4 antibodies. This may reflect CPM blocking the priming and 
proliferation of other important immune cell subsets required for effective vaccination, e.g. 
tumor-antigen specific effector T-cells and dendritic cells18,19 Further in-depth 
characterization is ongoing to decipher the exact effect of metronomic oral CPM on 
immunological responses, and how it might impinge on other cell populations. 
Saito et al. recently hypothesised that depletion of Foxp3hi suppression-competent Tregs 
abundant in CRC may provide clinical benefit,20 and this trial appears to corroborate this. A 
number of studies have indicated a better prognosis when tumors are infiltrated with 
relatively high numbers of Foxp3+ Tregs.21-23 Our previous studies demonstrated that as 
tumors advance, peripheral Treg proportion and suppressive capacity increase;10 in 
addition Treg depletion significantly improves anti-tumor immune responses in mice24 and 
CRC patients.9,10,25 In this trial, when Tregs were most effectively depleted, median PFS 
doubled (2.5 to 5.0 months). Although our evidence is limited to depletion of peripherally-
derived Foxp3+ Tregs, the prolongation in PFS indicates effective tumor control via the 
probable concurrent depletion of intratumoral Tregs, thus releasing the brake on 
intratumoral effectors. Hence it seems highly plausible that colorectal tumor-specific Tregs, 
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certainly in advanced disease, are detrimental to patients, and high pre-existing Foxp3+ 
Treg infiltration is merely a bystander effect of a larger anti-tumor immune response.26 
Regardless of mechanism, patients mounting anti-5T4 responses during CPM-treatment or 
TroVax vaccination were associated with a statistically significant increase in PFS and OS. 
In keeping with previous trials of TroVax,	whereby intramuscular injection of 1x109 TCID50 
TroVax induced the strongest immune response correlating with disease control,17,27,28 the 
vaccine was shown to be safe, well-tolerated, and the induction of an anti-5T4 immune 
response did not result in any detrimental off-target autoimmunity.  
Prior chemotherapeutic regimens in this metastatic CRC patient group appeared to have 
little effect on responses to either immunotherapeutic treatment (table 1), although some 
patients began the trial with relatively high pre-existing anti-5T4 responses, potentially 
induced by prior treatments. We found no evidence of pre-existing responses correlating 
with improved outcomes, although patients with higher pre-existing 5T4 antibody levels 
exhibited significantly higher 5T4 antibody responses to TroVax during treatment (data not 
shown). 
Large increases in Tregs occurred in several patients regardless of prior CPM treatment, 
in particular amongst HLA-DR1+/DQ5+ patients following a single TroVax injection (data 
not shown). Whilst this factor, alongside increased MVA antibodies (eFigure2), initially 
suggested the induction of peripheral tolerance to TroVax, anti-5T4 T-cell and antibody 
responses remained largely unaffected. There was also no correlation between high anti-
MVA titres and low anti-5T4 responses, although an association was identified between 
large increases in anti-MVA titres and PFS, but not OS (eFigure2), indicating that general 
patient health and immunocompetence may play a role in responsiveness to 
immunotherapy. Given that T-cell responses to the control antigen tuberculin-PPD varied 
little during the trial, nor associated with patient outcome (eFigure5), this suggests that the 
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key immune responses are those generated against tumor antigens, e.g. 5T4. This 
evidence supports exploring the use of TroVax (and other cancer vaccines29) earlier in the 
disease course.  
In summary, this randomized trial identified a subset of ‘immunotherapy-responsive’ 
mCRC patients demonstrating better tumor control when given either CPM or TroVax. 
Although CPM failed to enhance TroVax immunogenicity, clear survival benefits with 
minimal side effects were demonstrated and further investigation is warranted. Given 
CPM’s ineffectiveness in sustained Treg depletion during TroVax vaccination, we would 
propose the combination of TroVax with more potent blockade of tumor-derived 
immunosuppression for future development, for example with anti-CTLA-4 to eliminate 
intratumoral Treg,30 or with anti-LAG-3 checkpoint inhibitors, given the extent of infiltration 
of highly suppressive LAG-3+CD4+ tumor-infiltrating T-cells.31 
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Figure 1. TaCTiCC treatment schedule. 
50mg CPM was given twice daily at treatment days 1-7 (week 1) and 15-21 (week 3) to 
groups 2 & 4. 1x109 TCID50 TroVax was given as an intramuscular injection at treatment days 
22 (week 4), 36 (week 6), 50 (week 8), 64 (week 10), 78 (week 12) and 106 (week 16) to 
groups 3 & 4. 
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Figure 2. CONSORT flow diagram of study enrollment. 
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Figure 3. Improved progression-free survival of patients with sufficient Treg 
depletions in response to CPM.  
Peripheral Foxp3+ regulatory T-cells were enumerated by initially counting the CD3+CD4+ 
T-cells in whole blood, followed by phenotypic analysis to determine the proportion of 
CD4+ T-cells expressing Foxp3, an example of the gating strategy is shown (A). Overall 
Treg numbers are shown at indicated time points during CPM treatment (B: Blue circles: 
CPM-treated patients (n=27); Green triangles: Control (group 1) patients (n=8)). The 
maximum % decrease in absolute CD4+Foxp3+ Treg numbers during TD4-22 when 
compared to baseline was measured (C). The threshold for positive response was set at 
	 26 
the upper 95%-CI interval of 39.4% Treg depletion, those patients meeting this criterion 
are highlighted in blue (n=12). (D) Kaplan Meier survival curves for three groups of 
patients: CPM responders (>39.4% Treg depletion; blue line, n=12); CPM non-responder 
(black line, n=15); control group (green line, n=8). The median PFS among CPM 
responders was 5.0 months, as compared to 2.5 months for poor / non-responders and 2.5 
months for controls (HR 0.48 (95% CI 0.21-1.11); p=0.09). 
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Figure 4. Anti-5T4 immunological responses associate with survival.  
(A) 5T4-specific antibody levels were measured from plasma samples taken throughout 
the course of the trial. (B) The fold increases in 5T4-specific IFN-g+ T-cell and antibody 
responses were calculated by dividing the highest response to treatment at TD8-106 by 
baseline (TD1) level. TroVax® recipients (groups 3 & 4) demonstrating a >2-fold increase 
in both anti-5T4 T-cell and antibody responses at any point during the trial are highlighted 
in blue (n=16). These patients exhibited significantly prolonged PFS (C: HR 0.21 (95% CI 
0.090-0.47); p<0.001) and OS (D: HR 0.32 (95% CI 0.14-0.74); p=0.008) over TroVax® 
non-responders.  
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Figure 5. Survival by trial group.  
Survival outcomes of all patients by trial group is indicated for PFS (A) and OS (B). 
Survival outcomes of patients receiving any treatment (groups 2, 3 and 4, n=44) versus no 
treatment control (group 1, n=8) is indicated for PFS (C: HR 0.41 (95% CI 0.20-0.88); 
p=0.02) and OS (D: HR 1.03 (95% CI 0.43-2.47); p=0.95).  
 
